Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, PR China.
Eur Urol. 2010 Sep;58(3):442-9. doi: 10.1016/j.eururo.2010.05.046. Epub 2010 Jun 9.
Radical cystectomy (RC) with pelvic lymph node dissection (PLND) is the standard treatment for muscle-invasive and high-risk non-muscle-invasive bladder cancer (BCa). Large series with long-term oncologic data after laparoscopic RC (LRC) are rare.
To report oncologic outcomes of LRC for 171 cases with a median 3-yr follow-up.
DESIGN, SETTING, AND PARTICIPANTS: From December 2002 to June 2009, 171 consecutive patients with BCa who underwent LRC with orthotopic ileal neobladder (OIN) at our institution were enrolled in this retrospective study.
All patients underwent LRC OIN. Adjuvant chemotherapy was administered to patients with non-organ-confined disease or positive lymph nodes.
The demographic, perioperative, complication, pathologic, and survival data were collected and analysed.
Most tumours were transitional cell carcinoma (TCC; 160, 93.6%). Tumours were organ confined in 113 patients (pT1-T2; 66.1%) and non-organ confined in 58 patients (pT3-T4a; 33.9%). There was involvement of the lymph nodes in 38 patients (22.2%). Surgical margins were all tumour free. The mean number of removed lymph nodes was 16 (5-46). Follow-up ranged from 3 to 83 mo, and 54 (31.6%) patients completed 5-yr follow-up. Two patients (1.2%) had local recurrence and distant metastasis, 9 patients (5.3%) had local recurrence alone, and 23 patients (13.5%) had distant metastasis. One patient (0.6%) had port-site seeding. One hundred twenty-four patients (72.5%) were alive with no evidence of recurrence; 28 patients (16.4%) died, 20 from metastasis and 8 from tumour-unrelated causes. The estimated 5-yr overall survival, cancer-specific survival, and recurrence-free survival rates were 73.7%, 81.3%, and 72.6%, respectively. The relatively low percentage of patients reaching 5-yr follow-up is a limitation of this retrospective study.
Surgical technique of LRC with OIN can achieve the established oncologic criteria of open surgery, and our oncologic outcome is encouraging. Long-term follow-up is needed for further confirmation.
根治性膀胱切除术(RC)加盆腔淋巴结清扫术(PLND)是肌层浸润性和高危非肌层浸润性膀胱癌(BCa)的标准治疗方法。腹腔镜 RC(LRC)后具有长期肿瘤学数据的大型系列研究很少见。
报告 171 例接受 LRC 治疗的患者的肿瘤学结果,中位随访时间为 3 年。
设计、地点和参与者:2002 年 12 月至 2009 年 6 月,我院收治的 171 例膀胱癌患者连续接受 LRC 加原位回肠代膀胱术(OIN),进行回顾性研究。
所有患者均行 LRC-OIN 术。非器官局限性疾病或淋巴结阳性患者接受辅助化疗。
收集并分析了人口统计学、围手术期、并发症、病理和生存数据。
大多数肿瘤为移行细胞癌(TCC;160,93.6%)。113 例患者肿瘤局限于器官内(pT1-T2;66.1%),58 例患者肿瘤非器官内(pT3-T4a;33.9%)。38 例患者淋巴结受累(22.2%)。手术切缘均无肿瘤。切除的淋巴结平均数量为 16 个(5-46 个)。随访时间 3-83 个月,54 例(31.6%)患者完成 5 年随访。2 例(1.2%)患者出现局部复发和远处转移,9 例(5.3%)患者仅出现局部复发,23 例(13.5%)患者出现远处转移。1 例(0.6%)患者出现切口种植。124 例(72.5%)患者存活且无复发证据;28 例(16.4%)死亡,20 例死于转移,8 例死于肿瘤无关原因。估计 5 年总生存率、癌症特异性生存率和无复发生存率分别为 73.7%、81.3%和 72.6%。回顾性研究的局限性在于仅有相对较低比例的患者达到 5 年随访。
LRC 加 OIN 的手术技术可以达到开放手术的既定肿瘤学标准,我们的肿瘤学结果令人鼓舞。需要长期随访以进一步证实。